Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review

被引：0

作者：

Gonzalez, Anna ^{[1
]}

Kistenfeger, Quinn ^{[2
]}

Cosgrove, Casey M. ^{[1
]}

机构：

[1] Ohio State Univ, James Canc Hosp & Solove Res Inst, Comprehens Canc Ctr, Div Gynecol Oncol, Columbus, OH 43210 USA

[2] Ohio State Univ, Div Obstet & Gynecol, Columbus, OH USA

来源：

INTERNATIONAL JOURNAL OF WOMENS HEALTH | 2024年 / 16卷

关键词：

Niraparib; ovarian cancer; maintenance therapy; recurrent; PHASE-III TRIAL; MAINTENANCE THERAPY; COST-EFFECTIVENESS; RECURRENT; BEVACIZUMAB; INHIBITOR; CHEMOTHERAPY; MANAGEMENT; OLAPARIB;

D O I：

10.2147/IJWH.S466250

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

The advent of poly(ADP-ribose) polymerase (PARP) inhibitors has resulted in a significant paradigm shift in ovarian cancer treatment. Niraparib, a potent PARP inhibitor, has demonstrated substantial efficacy in both first-line and recurrent disease settings. By targeting homologous recombination DNA repair, a pathway frequently disrupted in ovarian cancer, particularly in the context of BRCA mutations, niraparib induces synthetic lethality. Pivotal clinical trials, including PRIMA, ENGOT-OV16/NOVA, and QUADRA, have solidified niraparib's role in the treatment paradigm. While sharing a common mechanism of action with other PARP inhibitors, niraparib exhibits a distinct toxicity profile. Notably, hematologic toxicities, particularly thrombocytopenia, and hypertension have been observed at Grade 3-4 levels. A comprehensive understanding of niraparib's efficacy and safety is essential for optimal patient selection and management.

引用

页码：2339 / 2346

页数：8

共 27 条

[1] Torre LA, Trabert B, DeSantis CE, Et al., Ovarian cancer statistics, 2018, Ca a Cancer J Clinicians, 68, 4, pp. 284-296, (2018)
[2] Fleming GF, Seidman J, Lengyel E, Et al., Epithelial ovarian cancer, Principles and Practice of Gynecologic Oncology, pp. 611-705, (2017)
[3] Bristow RE, Chang J, Ziogas A, Anton-Culver H., Adherence to treatment guidelines for ovarian cancer as a measure of quality care, Obstet Gynecol, 121, pp. 1226-1234, (2013)
[4] Ovarian Cancer NCCN Guidelines—version 3. 2024
[5] Lau CH, Seow KM, Chen KH., The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review, Int J Mol Sci, 23, 15, (2022)
[6] Doig KD, Fellowes AP, Fox SB., Homologous recombination repair deficiency: an overview for pathologists, Mod Pathol, 36, 3, (2023)
[7] Jones P, Wilcoxen K, Rowley M, Toniatti C., Niraparib: a Poly(ADP-ribose) polymerase (PARP) Inhibitor for the treatment of tumors with defective homologous recombination, J Med Chem, 58, 8, pp. 3302-3314, (2015)
[8] Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E., PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance, Front Cell Dev Biol, 8, (2020)
[9] Lord CJ, Ashworth A., PARP inhibitors: synthetic lethality in the clinic, Science, 355, 6330, pp. 1152-1158, (2017)
[10] Kurnit KC, Avila M, Hinchcliff EM, Coleman RL, Westin SN., PARP inhibition in the ovarian cancer patient: current approvals and future directions, Pharmacol Ther, 213, (2020)

← 1 2 3 →